title: Impact of patent ductus arteriosus and subsequent therapy with ibuprofen on the release of S-100B and oxidative stress index in preterm infants.
abstract: BACKGROUND
  Hemodynamically significant patent ductus arteriosus (hsPDA) leads to injury in tissues/organs by reducing perfusion of organs and causing oxidative stress. The purpose of this study was to evaluate the oxidant/antioxidant status in preterm infants with hsPDA by measuring the total antioxidant capacity and total oxidant status and to assess neuronal damage due to oxidant stress related to hsPDA.
  
  
  METHODS
  This prospective study included 37 low-birth-weight infants with echocardiographically diagnosed hsPDA treated with oral ibuprofen and a control group of 40 infants without PDA. Blood samples were taken from all infants, and than the total antioxidant capacity (TAC), total oxidant status (TOS), and S-100B protein levels were assessed and oxidative stress index was calculated before and after therapy.
  
  
  RESULTS
  The mean pre-therapy TOS level and oxidative stress index (OSI) value of the patients with hsPDA were significantly higher, but TAC level was lower than in the control group. There were no statistically significant differences in the mean post-therapy values of TOS, TAC, OSI, and S-100B protein between the two groups.
  
  
  CONCLUSIONS
  hsPDA may cause cellular injury by increasing oxidative stress and damaging tissue perfusion; however the brain can compensate for oxidative stress and impaired tissue perfusion through well-developed autoregulation systems to decrease tissue injury.
authors.affiliation: Department of Pediatrics, Division of Neonatology, Yuzuncu Yil University School of Medicine, Van, Turkey.
authors.forename: Nihat
authors.initials: N
authors.lastname: Demir
authors.affiliation: Department of Pediatrics, Division of Cardiology, Yuzuncu Yil University School of Medicine, Van, Turkey.
authors.forename: İbrahim
authors.initials: İ
authors.lastname: Ece
authors.affiliation: Department of Pediatrics, Division of Neonatology, Yuzuncu Yil University School of Medicine, Van, Turkey.
authors.forename: Erdal
authors.initials: E
authors.lastname: Peker
authors.affiliation: Department of Pediatrics, Yuzuncu Yil University School of Medicine, Van, Turkey.
authors.forename: Sultan
authors.initials: S
authors.lastname: Kaba
authors.affiliation: Department of Pediatrics, Yuzuncu Yil University School of Medicine, Van, Turkey.
authors.forename: Lokman
authors.initials: L
authors.lastname: Ustyol
authors.affiliation: Department of Medical Biochemistry, Yuzuncu Yil University School of Medicine, Van, Turkey.
authors.forename: Ragıp
authors.initials: R
authors.lastname: Balahoroğlu
authors.affiliation: Department of Pediatrics, Division of Neonatology, Yuzuncu Yil University School of Medicine, Van, Turkey.
authors.forename: Oğuz
authors.initials: O
authors.lastname: Tuncer
mesh_terms: D000975:Antioxidants; D016022:Case-Control Studies; D004374:Ductus Arteriosus, Patent / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D007052:Ibuprofen / Q000494:pharmacology / Q000627:therapeutic use*; D007231:Infant, Newborn; D007234:Infant, Premature / Q000378:metabolism*; D008297:Male; D018384:Oxidative Stress / Q000187:drug effects; D064568:S100 Calcium Binding Protein beta Subunit / Q000378:metabolism*
chemical_list: D000975:Antioxidants; D064568:S100 Calcium Binding Protein beta Subunit; D007052:Ibuprofen